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Abstract
Background: Shockwave therapy (SWT) is a commonly used intervention for a number of musculoskeletal
conditions with varying clinical outcomes. However, the capacity of SWT to influence pathophysiological processes
and the morphology of affected tissues remains unclear. The objective of the current review is to evaluate changes
in imaging outcomes of musculoskeletal conditions following SWT.
Methods: A comprehensive search of Medline, Embase, Cochrane Controlled Trials Register, CINAHL and
SportDiscus was conducted from inception to October 2018. Prospective clinical trials evaluating the effectiveness
of SWT based on changes in imaging outcomes were eligible for inclusion. Articles were evaluated independently
for risk of bias using the Cochrane Risk of Bias list and the Methodological Index for Non-Randomized Studies.
Random-effects meta-analysis and meta-regression with a priori determined covariates was conducted for each
condition to determine potential predictors of SWT effects.
Results: Sixty-three studies were included, with data from 27 studies available for effect size pooling. Meta-analyses
and meta-regression on imaging outcomes were performed for rotator cuff calcific tendinitis (n = 11), plantar
fasciitis (n = 7) and osteonecrosis of the femoral head (n = 9). There was an overall reduction in the size of
measured lesion following SWT (MD 8.44 mm (95%CI -4.30, 12.57), p < 0.001) for calcium deposit diameter, (MD 0.92
mm (95%CI -0.03, 1.81), p = 0.04) for plantar fascia thickness and (MD 4.84% (95%CI -0.06, 9.75), p = 0.05) for lesion
size in femoral head osteonecrosis. Meta-regression showed no influence of SWT dosage parameters, however,
baseline lesion size was an independent predictor for changes in imaging outcomes.
Conclusions: SWT altered the morphology of musculoskeletal conditions, potentially reflecting changes in
underlying pathophysiological processes. The parameters of SWT dosage are not significant predictors of changes
in imaging outcomes. Lack of adequate reporting of imaging outcomes limited the conclusions that could be
drawn from the current review. Registration number: PROSPERO CRD42018091140.
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Background
Shockwave Therapy (SWT) is used to treat a range of
musculoskeletal conditions. Focused and radial shockwave
(radial pressure waves) are two technically distinct forms
of SWT. It has been argued that focused shockwave ther-
apy and radial shockwave therapy should be viewed as dis-
tinctly different therapeutic modalities [1]. However,
despite the differences in their physical characteristics,
method of energy generation and shockwave propagation,
focused and radial shockwave types share common clinical
indications [2]. SWT is often indicated as a secondary
conservative treatment choice for recalcitrant musculo-
skeletal conditions, unresponsive to standard care [1, 3].
These indications include plantar fasciitis, Achilles tendino-
pathy, patellar tendinopathy, calcific and non-calcific shoul-
der tendinopathy and lateral epicondylitis. Also, bone and
cartilage related disorders such as non-union of fractures,
osteonecrosis of the femoral head and knee osteoarthritis re-
lated bone marrow edema (BME) are among the range of
SWT clinical indications. Research evidence for SWT clinical
effectiveness varies across the indicated conditions. Good evi-
dence based on systematic reviews exists to support the use
of SWT for calcific tendinopathy of the shoulder [4], Achilles
tendinopathy [5, 6], knee osteoarthritis [7], early stage osteo-
necrosis of the femoral head [8] and plantar fasciitis [9].
However, research evidence for the effectiveness of SWT in
lateral epicondylitis is variable [1] and is lacking for patellar
tendinopathy [3, 6].
Focused shockwaves are generated through three mecha-
nisms: electrohydraulic, piezoelectric or electromagnetic
methods that convert electrical energy into kinetic energy,
whilst radial shockwaves are generated pneumatically [2].
The proposed mechanism of action for SWT is based on
mechano-transduction [10]. The delivery of mechanical
acoustic energy to the target tissue induces molecular, cellu-
lar and tissue responses [11]. Based on animal studies, SWT
promotes the expression of various angiogenic and osteo-
genic growth factors such as vascular endothelial growth fac-
tor (VEGF) and bone morphogenetic protein (BMP), which
promotes tissue regeneration [12]. In addition, SWT has an
anti-inflammatory effect by modulating the expression of in-
terleukins (IL-6 and IL-10) and other cytokines [13].
Clinical outcomes such as pain rating and functional dis-
ability scores are commonly used to evaluate the effective-
ness of SWT. However, the utilization of objective outcome
measures that evaluate changes in the affected musculoskel-
etal tissues is required to provide evidence of SWT influence
on pathophysiological processes in humans. Different im-
aging techniques are used clinically to establish a diagnosis,
guide the delivery of an intervention or to evaluate the effect-
iveness of an intervention. A range of imaging modalities in-
cluding magnetic resonance imaging (MRI), ultrasonography
(US), Computed Tomography (CT), dual-energy x-ray ab-
sorptiometry (DEXA) or plain radiography have been used
to support diagnosis and in some cases to evaluate outcomes
in studies investigating SWT. Despite lack of consistency in
utilization, these imaging modalities are valuable tools for
evaluating the morphological characteristics of injured tis-
sues. That can then be used clinically to monitor improve-
ments in the underlying pathophysiological process following
an intervention. Therefore, the utilization of suitable imaging
tools at appropriate time points as an adjunct to clinical exam-
ination may provide a better understanding of the tissue
pathophysiology and support the management planning
process. Little is known about the capacity of SWT to induce
positive improvements in pathophysiological processes in
musculoskeletal disorders, as indicated by changes in imaging
parameters and no systematic reviews have been conducted
on this topic. Therefore, the primary aim of this review was to
explore the available evidence from clinical prospective trials
with regard to any changes in the morphology of musculo-
skeletal lesions following SWT, as measured by imaging pa-
rameters. The secondary aim was to investigate significant
predictors for the SWT effects using meta-regression. We also
sought to make recommendations for future research studies.
Methods
Protocol and registration
This systematic review and meta-analysis was conducted
following the guidelines of the Preferred Reporting Items
for Systematic Reviews and Meta-analyses (PRISMA).
The protocol of the current review was registered on the
International Prospective Register of Systematic Reviews
(PROSPERO; 2018, CRD42018091140).
Search strategy
A comprehensive search using the electronic databases
of MEDLINE, EMBASE, CINAHL, SPORTDiscuss and
the Cochrane Controlled Trials Register using the
PICOS format (population, intervention/exposure, com-
parison, outcome and study design) was conducted in
October 2018. A range of keywords integrated with sub-
ject headings relevant to the review were systematically
searched to maximize the search results. Keywords for
the population category contained terms related to mus-
culoskeletal conditions such as arthritis, fractures, bone
marrow edema and tendinopathies. The intervention
category contained keywords related to shockwave ther-
apy. The outcome category contained terms related to
different imaging methods (e.g. X-ray, MRI, Ultrasound
imaging). No specific comparator was added as the pri-
mary aim of the review was to examine post intervention
imaging changes. An example of the basic search strat-
egy for databases is presented in Additional file 1.
Eligibility criteria included prospective study designs
to avoid any potential selection bias inherent in retro-
spective studies, adult participants of both genders with
an established musculoskeletal diagnosis and reported
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pre and post imaging measures to facilitate evaluation of
changes in affected tissue morphology following SWT of
any type (focused and radial). Non-human and non-
English language studies were excluded.
Study identification
The principal author conducted the database search.
Study screening was carried out using the Covidence
platform [14]. Two independent reviewers (HA and SA)
screened titles and abstracts to determine eligibility for
inclusion. The decision to include or exclude studies,
based on the eligibility criteria, was made independently
by each author. Full-texts of potentially relevant studies
were retrieved for further assessment. Discrepancies in
opinions were resolved by a third senior reviewer (AW).
Risk of bias assessment
The quality of studies was independently evaluated by two
reviewers (HA and SA). A third senior reviewer (AW) was
involved to resolve differences in assessment. Randomized
Controlled Trials (RCTs) were evaluated using the
Cochrane Risk of Bias list [15]. The tool evaluates the risk
of bias in five domains (selection, performance, attrition,
reporting and other) for seven elements to be judged as
high, unclear or low risk. A three-point scale was used to
assign each degree of risk a number value with higher
numbers indicating a lower risk of bias (low risk = 2, un-
clear risk = 1 and high risk = 0). The maximum score of 14
indicates the lowest risk of bias for a given study.
The Methodological Index for Non-Randomized Stud-
ies (MINORS) tool [16, 17] was used to evaluate the
non-randomized studies. The MINORS is a valid and re-
liable tool that contains 12 methodological items, the
first eight items measure attributes specific to non-
comparative studies. Four additional items are evaluated
only for studies with comparative groups. A higher score
indicates a lower risk of bias.
The risk of bias was assessed mainly at the reported mea-
sured imaging outcomes level. The score for each risk of bias
tool was divided by the total number of points possible to
calculate the risk of bias percentage for each study.
Data extraction
One reviewer (HA) extracted relevant data from individ-
ual studies and the data were independently checked by
a second reviewer (SA) for consistency. Extracted data
included study characteristics such as study design, par-
ticipant numbers and demographics, the condition
treated, parameters and dosage of the SWT intervention
(level of energy, number of shocks and sessions), follow-
up period, imaging modality description and findings.
Authors were contacted when relevant outcomes were
incompletely reported and were asked to provide miss-
ing information. When the values of standard deviations
(SD) were not provided for the intervention or control
group, these were calculated from confidence intervals,
and p-values for differences in means, or for group
means using the RevMan calculator [18].
Primary outcome
Changes in measures derived from imaging methods
such as MRI, ultrasonography, CT, DEXA or plain radi-
ography reflecting morphological changes in affected
musculoskeletal tissues following SWT were the primary
evaluated outcomes for this review. The measures of ef-
fect were pre to post-imaging changes, demonstrating
presence, grade, signal intensity or size of the tissue le-
sion. The strategy for data synthesis employed a quanti-
tative method in the form of meta-analysis depending
upon the type of data extracted, alongside narrative
qualitative synthesis. The method of evaluation for each
study is clearly stated in the relevant tables.
Statistical analysis
Quantitative data analysis was performed using RevMan
[18]. Meta-analysis was conducted to calculate pooled ef-
fect size for included studies. Continuous data were pre-
sented as mean differences (MD) and dichotomous data
with odds ratios (OR), including the corresponding 95%
confidence interval (CI). Pooling was performed using a
random effects model to provide summary effect size
owing to expected clinical and methodological heterogen-
eity. Subgroup analyses were performed separately for
each musculoskeletal condition based on SWT type or
dosage, control group or use of imaging guidance. Hetero-
geneity was assessed statistically with χ2 test and I2 statis-
tics and significance was set at p < 0.05. Meta-regression
was carried out to explain the source of heterogeneity
based on important mediating covariates such as SWT
dose parameters, baseline lesion size, utilization of
anesthesia and imaging guidance (determined a priori).
Results
Study selection and characteristics
The database searches resulted in 789 titles. (Fig. 1). Fol-
lowing the removal of duplicates and exclusion of re-
cords based on title and abstract screening, a total of 93
studies were available for full-text review. A total of 30
studies were further excluded with inappropriate study
design (predominantly retrospective studies) or lack of
imaging outcome as the most frequent reasons for ex-
clusion, leaving a final selection of 63 studies meeting
the inclusion criteria. Of the included studies, 30 used
an RCT design and the remaining 33 studies were pro-
spective cohort trials.
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Description of included studies
The total number of participants in the SWT groups (fo-
cused and radial SWT) was 3110. The most commonly eval-
uated musculoskeletal condition was rotator cuff calcific
tendinitis (23 studies), followed by plantar fasciitis (13 stud-
ies), femoral head necrosis (12 studies) and fracture non-
union (4 studies). There were a few other individual studies
evaluating different musculoskeletal conditions (Fig. 2).
Quality assessment
The risk of bias assessment is summarized in Additional file 2
for included RCTs and prospective trials respectively. The
mean score (%) ± SD of the Cochrane risk of bias tool among
the 31 RCT studies was 59.68 ± 18.95, while the mean score
was 73.61 ± 7.65 for non-RCT studies according to the MI-
NORS tool. Items of risk of bias rating across all included
RCT and non-RCT studies are shown in Additional file 2.
Inter-rater reliability of the risk of bias assessment was calcu-
lated using the kappa coefficient (k). The overall agreement
between the two primary reviewers was 79.84% (k = 0.53) in-
dicating moderate agreement.
Rotator cuff calcific tendinitis
There were 23 studies (8 RCTs) published between 1995
and 2017 evaluating the effect of SWT on rotator cuff
calcific tendinitis. The total sample was 1110 (1141
Fig. 1 PRISMA flow chart of study selection process
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shoulders) participants. The main imaging inclusion cri-
terion for participant recruitment was the presence of
symptomatic type I or II calcification of the rotator cuff
based on the Gartner and Simons radiographic classifica-
tion [19], as detected on radiographs. Detection of gleno-
humeral or acromioclavicular arthritis, rotator cuff tear or
type III calcification were the main exclusion criteria.
Focused type SWT was used in 21 studies, while two
studies used radial type SWT. The mean ± SD SWT deliv-
ered shocks was 2104 ± 990.57 (1000–6000) and the mean
energy flux density (EFD) was 0.26 ± 0.15 (0.02–0.6) mJ/
mm2. The mean number of SWT sessions was 2.66 ± 1.91
(1–8) with 10.1 ± 7.26 (1–35) days interval between ses-
sions. Ten studies used anesthesia prior to SWT applica-
tion and 14 studies used imaging guidance to target
calcium deposits. Further details on included studies char-
acteristics and SWT parameters are presented in Table 1.
Plain radiographs obtained at different time points
post SWT was the method used to assess imaging out-
comes in 21 studies, while two studies used ultrasonog-
raphy. Four studies reported the change in calcium
deposit diameter (mm), 16 studies reported the number
of participants demonstrating total calcification resorp-
tion and three reported on reduction or fragmentation
of the calcium deposit (Table 2).
The size of calcium deposit was shown to reduce fol-
lowing SWT application (MD 8.44 mm (95%CI 4.30,
12.57), p < 0.001; Fig. 3) within a period of 1 week [21],
3 months [36] and 12 months [26, 29, 31]. Baseline cal-
cium deposit size was the only covariate to explain the
variance related to the effect of SWT (Coeff. 1.38 mm
(95%CI 0.98, 1.77) I2 = 43.55%, Adj. R2 = 99.18%, p =
0.002). No variables related to SWT treatment parame-
ters were significant covariates.
The reduction in calcium deposit size favored SWT
compared to placebo but did not reach statistical signifi-
cance (MD − 11.26 mm (95%CI -24.68, 2.17), P = 0.1)
[21, 29]. However, the effect of SWT on calcium deposit
size was less compared to ultrasound-guided needling
(MD 4.25 (95%CI 2.27, 6.24), p = 0.006), (Fig. 4) [26, 31].
Total calcium resorption was reported in 222/559 (35%)
shoulders. Total calcium resorption was greater in the
SWT group compared to placebo (OR 6.38 (95%CI 1.33,
30.70, p = 0.02), but not compared to ultrasound guided-
needling (OR 0.27 (95%CI 0.12, 0.64), p = 0.003), (Fig. 5).
Plantar fasciitis and heel spurs
A total of 13 studies (7 RCTs) published between 2008
and 2018 evaluated imaging changes in plantar fasciitis
following SWT. The total number of included partici-
pants was 359 (365 heels) diagnosed with symptomatic
heel pain in addition to imaging features of plantar fascia
thickening (> 4 mm) as the main inclusion criteria. The
main exclusion criteria were the presence of systemic
disease such as rheumatoid arthritis, diabetes mellitus,
vascular abnormalities or neurological impairments.
Eight studies utilized focused-SWT, radial-SWT was
used in three studies and one study employed a com-
bined focused and radial SWT type stimulus. The type
of SWT was not reported in one study [43]. The mean
SWT shocks per treatment session was 2426.92 ± 965.36
(1000–4000) with a mean EFD of 0.22 ± 0.14 (0.03–0.42)
mJ/mm2. The mean number of treatment sessions was
3.04 ± 1.67 (1–8) sessions with a mean of 24.79 ± 43.56
(1–140) days between sessions. Only two studies used
anesthesia before the application of SWT and four stud-
ies employed sonographic guidance to localize the area
of application (Table 3).
Fig. 2 Musculoskeletal conditions of included studies
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Table 1 Characteristics of studies and intervention details for rotator cuff calcifying tendinitis














































2 14 days None, yes
Cacchio
(2006) [21]
RCT 45 56.12 ±
1.98
14 ± 4.95 Seated with shoulder abducted
at 45o in external rotation,
elbow at 90o, SWT was placed











52.1 ± 48.5 Ultrasound was used to identify
the lesions and aimed at the
calcific deposit at all times.





RCT 35 51.8 15 (10–20) SWT was placed in the direction
of the calcification based on
sonographic examination














SWT was performed after
localization of the calcification in











> 6 NR 2500*0.1,
pressure of
2.5 bar




RCT 80 49 ± 7 NR The calcification was identified
by fluoroscopy in seated
position





RCT 15 49.7 ± 9 > 6 The calcific deposit was located
by fluoroscopy. The computer






























Using fluoroscopy in prone
position as the shoulder was













RCT 33 54.4 (30–
70)
12.3 (6–72) NR 1000*0.55 2 14 days None, yes
Jakobeit
(2002) [30]
80 53.3 > 6 SWT was performed with
retroversion and adduction of







RCT 29 57.4 (47–
78)
> 3 SWT was performed in the
sitting position by aiming at the
maximum sore spot according
to anatomic targeting








In prone position, the calcific
deposit had been positioned in
the center of the scan unit.







36 The calcification was visualized





1 week None, yes
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Table 1 Characteristics of studies and intervention details for rotator cuff calcifying tendinitis (Continued)































> 12 SWT was performed as
localization of the calcium
deposit was achieved with an
image intensifier that was
adjusted automatically in two











> 3 NR 2500*0.11 4 3 days None
Pan (2003)
[36]




SWT was positioned at the
marked painful area as defined











> 2 NR 2000*0.21 8 1 week None
Pleiner (2004)
[38]
RCT 23 (31) 54 ± 11 > 6 SWT was focused on the point
of maximum pain





40 47 25 (12–
120)
SWT was administered once the
calcium deposit is situated in
the center of the C-arm.








52.6 ± 54.4 SWT was administered once the
calcium deposit is situated in
the center of the C-arm
3000*0.6 1 NA Active exercise









> 6 In group 1, the angle and
distance between the SWT and
shoulder were adjusted until the
patient reported to the point of
maximum tenderness. In group
2, the Lithotrack device was
used to locate the calcium
deposit in the center of a
crosshairs by fluoroscopy in 2
planes. The computer calculated
the angle and distance to
provide maximum precision.
1000*0.08 3 1 week None
Tornese
(2011) [42]
RCT 35 52.6 NR Group A (Neutral position): the
subject lay supine with shoulder
in neutral rotation, the arm
placed alongside the trunk and
the hand resting on the
abdomen
Group B (Hyperextended
internal rotation): the subject lay
supine with shoulder in
hyperextension and internal
rotation with the hand placed
under the buttock and the palm
facing down
1800*0.22 3 1 week None
NSAIDs Nonsteroidal Anti-Inflammatory Drugs, NA not applicable, NR not reported
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Table 2 Imaging outcome measures for rotator cuff calcifying tendinitis
Author (year) SWT
type
Comparator Imaging outcome Follow-up











Low SWT The radiological aspects of
calcifications (i.e. type, size and
location) were determined through
lateral and anteroposterior
shoulder views in neutral, external
and internal rotation. Changes
were graded as no resorption,
partial resorption and total or
subtotal resorption (over 80%




High: 6(15%) had total or subtotal
resorption. 3(7.5%) had partial
resorption
Low: 2(5%) had total or subtotal







Placebo The radiological aspects of
calcifications (i.e. type, size and
location) were determined through
lateral and anteroposterior
shoulder views in 45 degrees of
external and internal rotation were
acquired. Type of calcification was
evaluated according to the Gartner
and Simons classification. A caliper
that evaluated calcification length
(in millimeters) was used for size
measurement.
1 week 39(86.6%) had total resorption,
6(13.4%) had partial resorption,
while the control group, no
complete disappearance of
calcifications was observed.
The mean Calcium deposits
diameter (mm) pre-SWT was
21.3 ± 7.5, post-SWT was 0.85 ± 1.2.
In contrast, pre-sham was 19.7 ±
8.3, post-sham was 18.85.8 ± 6.4.





None Calcific deposit appearance was





After 12 weeks, 2/30 had total
resorption. 5 deposits had partial
resorption.
After 24 weeks, 5/29 had total







Placebo Variations in the dimension of the
calcification were evaluated by
anteroposterior views. Modification
of the calcification (a reduction of
size of > 2 mm) was indicated as
disintegration; the total
disappearance was indicated as
dissolution.
1 month 11(31%) had total resorption,
14(40%) had partial resorption.
Calcification remained unchanged






1 vs 2 sessions Anteroposterior radiograph in
internal and external rotation was
obtained to show obvious changes
in the shape and structure
(disintegration) or complete




30% in group A and 52% in group
B had partial or total resorption
after 3 months, 47 and 77% after 6
months and 93% for both groups
at 4 years








Scoring of calcification deposits
was assessed through the Gartner
Classification of Calcific Tendinitis.
6 weeks 1/14 (7%) in the R-SWT group had












Calcification size measurement was
assessed by ultrasound imaging.
3,6,12
months
55.6% had total resorption by 12
months in the SWT group vs
86.78% in the UGPL group.
The mean Calcium deposits
diameter (mm) pre-SWT was
10.53 ± 5.29, post-SWT was 4.67 ±
6.08 after 12 months. In contrast,
pre-UGPL was 12.075 ± 4.85, post-
UGPL was 1.56 ± 2.79.





Low SWT Radiological difference of the





58% improved in group A
compared to 69% in group B after
12 weeks.
5 in group A, and 4 in group B
had total resorption
NR NR
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Table 2 Imaging outcome measures for rotator cuff calcifying tendinitis (Continued)
Author (year) SWT
type
Comparator Imaging outcome Follow-up













The radiological aspects of
calcifications (i.e. type, size and
location) were determined through
anteroposterior shoulder views in




High: 60% had total resorption
within 6 months and 86% after 12
months. Low: 21% had total
resorption within 6 months and
37% after 12 months. Placebo: 11%
had total resorption within 6
months and 25% after 12 months.
Calcific deposit size (mm2) mean
change from baseline after 12
months was − 162.2 (95%CI − 204
to −120) in the High-SWT group,
− 91.5 (95%CI − 148 to − 35.1) low-
SWT group and − 46.8 (95%CI
−74.3 to −19.3) in the placebo
group
NR group 1 vs 3
P < 0.01, group
2 vs 3 P = 0.1,






Placebo An anteroposterior radiograph
with the arm in neutral rotation
was obtained. The calcific deposits
were categorized according to
morphology and size (the longest
length of the calcium deposit).
Scoring of calcification deposits
was assessed through the Gartner




7(21.2%) had total resorption,
11(36.6%) had partial resorption. In
the control group, none had total
resorption and 2(15.3%) had partial
resorption.
The mean Calcium deposits
diameter (mm) pre-SWT was
11.9 ± 5.4 (3.4–23.5), post-SWT was
5.5 ± 6.3 (0–18.7). In contrast, pre-
sham was 10.5 ± 6.4 (2.5–20.4),
post-sham was 9.8 ± 5.9 (2.3–21).





None Diagnostic ultrasonography and
radiography were used to classify
the calcareous deposits in 5
categories according to their
morphological appearance and
size.
4 weeks 57/80 (71.25%) had total










performed by standard shoulder
anteroposterior radiographs in
neutral, internal, and external
rotation together with axillary and
supraspinatus outlet views to
determine the size, morphology,
and location of the calcific
deposits. Resorption of the calcific





The mean Calcium deposits
diameter (mm) pre-SWT was 11 ± 1
(4.9–19.3), post-SWT was 5.6 ± 0.8.
In contrast, pre-US needling was
14.8 ± 1.7 (6.6–31), post-US need-
ling was 0.45 ± 0.3.
In the SWT group, 42.6% had total
resorption, 16.7% had partial
resorption. In the US needling
group 72.2% had total resorption











taken in internal and external
rotation together with axial and
supraspinatus-outlet views to de-
termine the size, morphology and
location of the calcific deposits.
4.1 ± 0.5 In the SWT only group, 13(32.5%)
had total resorption, 14 (35%) had
partial resorption. In the US
needling combined with SWT
group 24(60%) had total resorption










anteroposterior view in internal
and external rotation and a
supraspinatus outlet view. Effective
treatment was recorded when the
calcification had completely
disappeared or showed obvious
resorption with inhomogeneity
and reduction in size
3,6
months
There was total resorption in 4/20
in group 1, 11/20 in group 2, 12/
20 in group 3, in contrast to 2/20












None Radiological assessment of the
calcification was made in three
6,12
weeks
After 12 weeks, changes were seen
in 12 patients; 7 showed a total
NR NA
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Table 2 Imaging outcome measures for rotator cuff calcifying tendinitis (Continued)
Author (year) SWT
type
Comparator Imaging outcome Follow-up












None Radiographs in anteroposterior of
shoulder, acromial outlet view and
sonography were evaluated to
study the type of calcium deposit
according to DePalma criteria
1,6
months
29/54 (54%) had total resorption
and 19/54 (35) had partial
resorption after 1 month. These








(HRUS) was used for imaging
measurements. The morphology of
calcific plaque of the shoulder on
HRUS was classified into 4 types:
(1) arc-shaped (echogenic arc with
clear shadowing), (2) fragmented
(at least 2 separated echogenic
plaques with or without shadow-
ing) or punctuated (tiny calcific
spots without shadowing), (3)
nodular (echogenic nodule with-
out shadowing), and (4) cystic




The mean of difference in Calcium
deposits diameter (mm) in the
SWT group was 4.39 ± 3.76 after
12 weeks. In contrast, the TENS
group was 1.65 ± 2.83.
16/33(48.5%) changed in the type
of calcification In the SWT group







None Radiological assessment of
anteroposterior, internal and
external rotation and trans-glenoid
projection was performed
1month 7/19 (37%) had reduction or







Placebo Anteriorposterior, axial and outlet-
view images were used. Changes
calcifications were assessed using
the Gartner scale in which a score
of 1: indicates no change or a
worsening, a score of 2: a decrease
of at least 50% in the area and
density of the calcification, and a




6/31 (19.4%) had total resorption
and 6/31 (19.4%) had partial
resorption in the SWT group, in
contrast to 2/26 (7.7%) had total
resorption and 2/26 (7.7%) had
partial resorption in the control






None On radiographs, any sign of
disintegration was rated as success
6,24
weeks
4/40 (10%) had total resorption
and 17/40 (42.5%) had partial
resorption after 6 weeks.
After 24 weeks, 6/40 (15%) had









On the anteroposterior radiological
views, resorption was graded as
none, partial, or complete.
12
months
47% had total resorption and 33%
had partial resorption in the SWT
group. In the surgical group, 85%
had total resorption and 15% had
partial resorption. There was no










No change in the radiographs was
graded as 4, a 3 indicated slight
alteration of the calcium deposit,
reduction in deposit size and
radiographic density was graded
as 2, and a 1 was given if the




6/25 (24%) had total resorption
and 7/25 (28%) had extensive
resorption in the navigation group,
in contrast to 1/25 (4%) had total
resorption and 5/25 (20%) had











Changes between pre- and post-
treatment radiographs were
graded as no resorption, partial re-
sorption and total or subtotal
3
months
12/18 (66.7%) had total resorption
in the hyperextended internal
rotation group, in contrast to 6/17
(35.3%) in the neutral position
NR < 0.05
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Ultrasonography was the most common method for
evaluating the imaging outcomes as reported in nine stud-
ies, followed by MRI in four studies. The change in plantar
fascia thickness (PFT) was evaluated in eight studies as the
most frequently reported imaging outcome (Table 4).
There was an overall reduction in PFT following SWT ap-
plication (MD 0.92mm (95%CI 0.03, 1.81), p= 0.04; Fig. 6)
at 4 weeks [55], 6 weeks [54], 3months [49, 53, 56] and 6
month follow-up [47, 51]. Subgroup analysis showed greater
reduction in PFT using radiological guidance (MD 1.31mm
(95%CI 0.49, 2.13), p= 0.002) versus no guidance (MD 0.47
mm (95%CI -0.28, 1.21), p= 0.22) (Fig. 7). Baseline PFT was
the only covariate to explain the variance related to the ef-
fect of SWT (Coeff. -1.06mm (95%CI − 1.59 to − 0.53)
I2 = 78%, Adj. R2 = 85.10%, p = 0.004). No variables related
to SWT treatment parameters were significant covariates.
The reduction of PFT favored SWT compared with cor-
ticosteroid injection (MD − 0.3 mm (95%CI -0.62-0.02),
p = 0.07) [49, 53, 54] and over placebo control (MD − 0.9
mm (95%CI − 1.56 to − 0.24), p = 0.007) [56]. However,
the effect of SWT on PFT was less compared to low-level
laser therapy and therapeutic ultrasound (MD 0.43mm
(95%CI 0.09, 0.78), p = 0.01) [55] (Fig. 8).
The bone resorption effect of SWT on calcaneal spurs
was evaluated in three studies (1 RCT) with a total of 461
participants. Chronic symptomatic heel pain (> 3months)
and radiological evidence of a calcaneal spur were the
main inclusion criteria. Radial SWT was used in two stud-
ies and one study employed focused SWT. None of the
studies utilized radiological guidance and only one study
used anesthesia [50]. The range of delivered shocks was
1500–2000 shocks carried in 1–5 sessions with 7–30 days
interval between each session (Table 3).
Morphological changes in calcaneal spurs were evaluated
using plain radiographs in two studies, while one study [46]
measured bone mineral density (BMD) and bone mineral
content (BMC) using DEXA scanning. None of the studies
reported calcaneal spur fragmentation or significant reduc-
tion of the spur dimensions [50, 57]. However, both BMD
and BMC demonstrated statistically significant improvement
following focused SWT after a 12week follow-up period, in-
dicating an osteogenic effect [46] (Table 4).
Osteonecrosis of the femoral head
The effects of SWT on osteonecrosis of the femoral head
(ONFH) were evaluated in 12 studies (4 RCTs) published be-
tween 2001 and 2018. These studies included 325 (404 hips)
participants with stage I-III ONFH according to the Associ-
ation Research Circulation Osseous (ARCO) classification as
the main inclusion criterion, except for one study [59] that
included ARCO stage I only. The main exclusion criteria
were late ARCO stages, infection, advanced arthritis, neo-
plastic disease or blood coagulation disorders.
All of the included studies employed focused SWT with
a mean EFD of 0.57 ± 0.06 (0.47–0.62) mJ/mm2 and a
mean of 4867.86 ± 1469.64 (2000–6000) shocks. All of the
included studies delivered the treatment over one session,
except Vulpiani et al. [60] who provided treatment over
four sessions and D’Agostino et al. [59] over two sessions
(2–3 days interval). Anesthesia was used in eight studies
and radiological guidance was implemented in nine stud-
ies to accurately target the site of lesion (Table 5).
Table 2 Imaging outcome measures for rotator cuff calcifying tendinitis (Continued)
Author (year) SWT
type
Comparator Imaging outcome Follow-up







position resorption (> 80% reduction in cal-
cified surface on anteroposterior
view)
group
F-SWT focused SWT, R-SWT radial SWT, NR not reported, NS not significant, NA not applicable
Fig. 3 Forest plot of effect of SWT on Calcium deposit diameter (mm) in rotator cuffcalcific tendinitis.
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Imaging changes of ONFH were measured utilizing MRI
in addition to radiography in all included studies to evaluate
the lesion size, femoral head congruency, presence of a cres-
cent sign, BME and degenerative changes of the hip joint.
The percentage of change in the osteonecrosis lesion size
was reported in eight studies (Table 6).
The size of the lesion (%) showed modest reduction
following SWT application with marginal statistical sig-
nificance (MD 4.84% (95%CI -0.06-9.75), p = 0.05; Fig. 9)
at 6 months [65], 12 months [70], 2 years [61, 63, 66–69]
and 3 years [62] follow-up. Baseline lesion size was the
only covariate to explain the variance related to the ef-
fect of SWT (Coeff. 0.87% (95%CI 0.48, 1.26) I2 = 6.2%,
Adj. R2 = 93.77%, p = 0.001). No variables related to
SWT treatment parameters were significant covariates.
The reduction in the lesion size generally favored SWT
compared to other interventions such as core decom-
pression [66, 68], cocktail therapy [63] and SWT com-
bined with alendronate [69] with an overall MD -8.50%
(95%CI − 16.40 to − 0.59), p = 0.04; Fig. 10.
Miscellaneous conditions
The remaining musculoskeletal conditions evaluated with
imaging measures following SWT were fracture non-
union [71–74], lateral epicondylitis [75, 76], knee osteo-
arthritis related BME [77, 78], Achilles tendinopathy [79],
post-traumatic myositis ossificans [80], arthroscopic rota-
tor cuff repair [81] and Kienbock’s disease [82]. Descrip-
tion of these studies is provided in Additional file 3.
Fig. 4 Forest plot of effect of SWT vs control on Calcium deposit diameter (mm) in rotator cuff calcific tendinitis
Fig. 5 Forest plot of effect of SWT vs control on total calcification resorption in rotator cuff calcific tendinitis
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Table 3 Characteristics of studies and intervention details for plantar fasciitis and heel spurs
Author Study
design












































to the painful and
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over the end of the
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Heel spur 45 53 (28.6–
80.1)







placed at the origin
of the fascia and
reached the central
calcaneus.































308 NR > 6 SWT was applied
from the plantar






















3800*0.36 1 or 2 3 months None
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Discussion
The aim of the current systematic review and meta-analysis
was to evaluate changes in the morphology of musculoskel-
etal structures as measured by imaging following a SWT (fo-
cused and radial) intervention. Overall, there was a tendency
for SWT to demonstrate morphological changes among
most of the included musculoskeletal conditions based on
different quantitative imaging methods. These tissue changes
tended to favor SWT over placebo or other comparators ex-
cept for rotator cuff calcific tendinitis that favored ultrasound
guided needling over SWT. Interestingly, SWT type (radial
and focused) and the therapeutic dosage parameters did not
appear to have a significant influence on the evaluated im-
aging outcomes according to our subgroup and meta-
Table 3 Characteristics of studies and intervention details for plantar fasciitis and heel spurs (Continued)
Author Study
design































54 35.2 (30–42) > 6 SWT was applied at
the medial tubercle
of the calcaneus, at
the proximal
insertion of the
plantar fascia or the
calcaneal spur,
around the point of
medial tenderness





30 34.27 ± 7.19 > 6 SWT was applied in
prone position over





























19 54.45 ± 6.9 27 ± 29.79 SWT was applied in
the prone position
into the areas of the
painful heel,
insertion of plantar
fascia on the medial
calcaneal area, and
myofascial junction
at the dorsum of the
heel















































1500*18kv 1 NA None, yes
NSAIDs nonsteroidal anti-inflammatory drugs, NA not applicable, NR not reported
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Table 4 Imaging outcome measures for plantar fasciitis and heel spurs
Author (year) SWT
type
Comparator Imaging outcome Follow-up











None MRI was used to assess changes in
the soft tissue and BME, plantar fascia
thickness (PFT) and the presence of
heel spurs. MRIs were scored semi-
quantitatively. PFT was measured 1 cm
from the insertion and thickness > 3




improvement in PFT. 21/30 (70%)
and 10/19(52.6%) had
improvement in soft tissue and
BME respectively. No significant











Ultrasonography of plantar fascia (PF)
was performed to manually measure
the point of maximal proximal PFT at




The median PFT improvement in
the ACP group at the 6-month
follow-up was 1.3 mm compared
with the SWT and conventional
treatment groups, which both













The mean PFT decreased from
5.84 to 5.21 in the females, and







None Measurements of bone mass density
(BMD) and bone mass concentration
(BMC) were performed with a Lunar
DEXA. The square-shaped analysis field
(Region of Interest, ROI) was placed in
the cancellous part of the calcanei
and BMD and BMC were measured.
6,12
weeks
The mean BMD (g/cm2) values
changed from 0.5 ± 0.1 to 0.557 ±
0.1 in the SWT group and from
0.54 ± 0.1 to 0.52 ± 0.09 in the
control group after 12 weeks.
The mean BMC (g) values
changed from 2.03 ± 0.38 to
2.22 ± 0.38 in the SWT group and
from 2.16 ± 0.4 to 2.08 ± 0.36 in






None The PFT was measured about 2 cm




The mean PFT in 16 subjects
changed from 5.2 ± 1.5 to 4.4 ± 1
after 6 months. There was no
significant change of PFT on the
control side









PFT and its echogenicity were
examined through ultrasonography. A
linear probe was positioned
longitudinally over the medial
tubercle of the calcaneus. PFT was
measured at the proximal point of
insertion of the fascia into the
calcaneal tubercle. A PFT of 4 mm was
considered evidence of fasciitis.
1,3,6
months
PFT was found to be significantly
reduced in both groups at all
measurement endpoints
compared with baseline with no
significant differences between
groups







PFT was measured at the PF insertion




At 4th week, the mean PFT
changed in SWT group from
0.37 ± 0.07 to 0.46 ± 0.08 cm, and
in the CSI group from 0.38 ± 0.06
to 0.43 ± 0.09 cm
At the 12th week, the mean PFT
changed in the SWT group from
0.37 ± 0.07 to 0.38 ± 0.07 cm, and
the CSI group from 0.38 ± 0.06 to
0.39 ± 0.07 cm








Placebo Axial, lateral, and oblique radiographs
of the calcaneus were performed to
examine the presence of any osseous
abnormalities of the calcaneus or for




205/308 (67%) in the EWST group
had an inferior calcaneal spur. In
the sham treatment group, 78/127
(61%) had a spur.
No patient treated with SWT had
subsequent fragmentation or
disappearance of the heel spur at
3 or 12 months. Similarly, no
patient had evidence of reactive
NR NR
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Table 4 Imaging outcome measures for plantar fasciitis and heel spurs (Continued)
Author (year) SWT
type
Comparator Imaging outcome Follow-up







new bone formation in or around






None On MRI, 4 items were examined: PFT,
high-signal intensity area (HSIA) inside
the PF, edema around the PF, and
BME of the calcaneus. For the PFT, the
maximum diameter of the PF at the
calcaneal attachment was measured
on T1-weighted coronal images.
6
months
The mean PFT changed from
4.4 ± 1.6 to 4.6 ± 1.8 after 6
months.
The numbers of feet showing
HSIA inside the PF changed from
15 to 6, in edema around the PF
from 16 to 2, and in BME of the






None A lateral weight-bearing X-ray of the






There was no heel spur
fragmentation observed. The
ultrasound evaluation at 24
months showed a complete
disappearance of the inflammatory










PFT was measured at the thickest
portion from the base of the medial
calcaneal tubercle where a bright





The mean PFT in the SWT group
changed from 5.93 ± 0.54 to
3.37 ± 0.42, and in the ultrasound
guided injection group from








Ultrasonography was performed in
prone position with ankles dorsiflexed.
The focus was adjusted to the depth
of the PF. The sonographic diagnosis
established based on: 1) fascial
thickening > 5 mm, 2) biconvex
morphology and 3) abnormal fascial
echostructure, specifically
hypoechogenicity, heterogeneity and
ill-defined margins. PFT was measured




In the SWT group, PFT with
perifascial edema was reduced to
4.6 ± 0.6 mm and up to 4 ± 0.3 mm
among PFT without perifascial
edema.
In the corticosteroid
Injection, PFT with perifascial
edema was reduced to
4.3 ± 0.4 mm and up to 4.6 ± 0.4











The maximum thickness of the
proximal PF where it attaches to the
calcaneus was measured using
electronic calipers on fluid-sensitive
MRI sequences in the sagittal and cor-
onal planes. The intrafacial and perifa-
cial soft tissue edema and calcaneal
BME were assessed in the sagittal
plane on short tau inversion recovery
sequences, and the presence of the




The mean PFT in the SWT group
changed from 5.17 ± 0.89 to
4.31 ± 0.82, in the LLLT group from
4.33 ± 0.59 to 3.75 ± 0.69, and in
the US group, from 4.76 ± 0.72 to










Placebo Sagittal imaging of the PF was
performed with the ultrasound
transducer aligned along the
longitudinal axis of the aponeurosis.
PFT was measured about 2 cm distal
of the medial calcaneal tuberosity.
Qualitative assessment was performed
including echogenic appearance of
plantar fascia and its fibrillary pattern
3
months
The mean PFT in the SWT group
changed from 4.1 ± 1.3 to 3.6 ± 1.2,
in the placebo group from 4.1 ±






None Lateral radiographs evaluated
variations in the dimensions of
calcaneal spurs. The radiographic
variations included classification as
reductions in the dimensions and the
NR No significant disappearance of
heel spurs, but 19(17.6%) had a
decrease in the angle of the spur,
23(21.3%) had a decrease in the
dimensions of the spur, and
NR NA
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regression analyses. Also, the utilization of imaging guidance
and use of anesthesia had no clear impact on the evaluated
imaging outcomes. The baseline size of the lesion was the
only factor that explained the heterogeneity in our findings.
However, these results should be interpreted with caution
due to the relatively small overall number of studies and sev-
eral potential sources of heterogeneity such as variation in
study design, variation in imaging methods and measures,
time period for imaging follow-up, high risk of bias and the
small number of trials included in the subgroup and meta-
regression analyses. In addition, SWT device related factors
may contribute to the heterogeneity such as different SWT
types. Further research is required to clearly determine
whether there are differences in response to focused or radial
SWT for different conditions.
Our meta-analysis data on the effect of SWT on rota-
tor cuff calcific tendinitis were comparable to a recent
meta-analysis [4] that reported total resorption occurred
more commonly using high- versus low-energy SWT at
3 months (OR: 3.4 (95% CI 1.35,8.58); p = 0.009) based
on 3 included studies of 163 participants. In addition to
reporting the chances of total resorption versus control, the
current meta-analysis has also reported within and between
groups changes in the size of the calcium deposit diameter
that have not been reported previously. A small number of
studies (5/23) reported quantification of the change in the size
Table 4 Imaging outcome measures for plantar fasciitis and heel spurs (Continued)
Author (year) SWT
type
Comparator Imaging outcome Follow-up












None Prior to MRI, a vitamin E capsule was
taped to the heel that could be
readily seen on MRI, where the point
of maximal intensity of pain was
delineated with a permanent marker.
MRI assessed the presence and
severity of soft tissue and calcaneal
marrow edema, heel spur and PFT.
24 h 16/18(89%) had subcutaneous soft
tissue and perifascial edema
before SWT. After SWT, all 18
showed subcutaneous soft tissue
and perifascial edema. Calcaneal
marrow edema was seen in 8
heels. After SWT, edema increased
in 1 heel and 1 new heel edema
was developed.
Heel spur was seen in 9(50%) that
was unchanged.
17(94%) had an abnormal PFT (>
4 mm) before SWT that remained
unchanged following SWT
NR NA
BME bone marrow edema, F-SWT focused SWT, R-SWT radial SWT, NA not applicable, NR not reported, NS not significant
Fig. 6 Forest plot of effect of SWT on plantar fascia thickness (mm)
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of calcium deposit diameter, which limited the power of the
current meta-analysis. Out of the five included studies in the
meta-analysis, Cacchio et al. [21] reported the highest rate of
total resorption (86.6%) and reduction in calcification deposit
size MD=20.45mm (18.23, 22.67) at one week follow-up
using a radial SWT device. The authors themselves did not
expect this high rate of resorption and attributed it to the fea-
ture of radial SWT that insures the whole calcification area is
included inside the wave propagation area. The only available
included comparable study is by De Boer et al. [25] that also
used a radial SWT device with similar treatment parameters
demonstrating a total resorption of only 7% at six weeks. Our
data comparison could provide an explanation related to the
initial size of the calcium deposit that was exceptionally high
in the Cacchio et al. [21] study (21.3 ± 7.5mm), which was the
only significant predictor in our meta-regression analysis. Lar-
ger deposits being more responsive to treatment.
According to our meta-analysis data, SWT demonstrated
significant reduction in PFT and associated calcaneal BME.
The reduction in PFT was greater when utilizing radio-
logical guidance, which might be due to more consistent
targeting of the SWT to the affected tissue area and
Fig. 7 Forest plot of effect of SWT on plantar fascia thickness (mm) based on radiological guidance
Fig. 8 Forest plot of effect of SWT vs control on plantar fascia thickness (mm)
Al-Abbad et al. BMC Musculoskeletal Disorders          (2020) 21:275 Page 18 of 26
Table 5 Characteristics of studies and intervention details for osteonecrosis of the femoral head (ONFH)
Author
(year)





























6 ± 3 The hip was fixed in adduction
and internal rotation, ONFH was
marked using fluoroscopy in 2–3














11.3 ± 3.4 Four points with 1 cm apart
within the junctional zone were
chosen with a metallic pin
under C-arm control, and the
corresponding locations were
marked on the skin in the groin
area. The depth of treatment
was adjusted until the two ring
markers of the device synchro-









20 43.23 4.2 (4–7)
weeks







7.2 ± 2.9 The hip joint was properly
positioned by abduction and
internal or external rotation. The
junctional zone between
avascular and normal bones of
the femoral head was

































SWT was focused around (on
the margins of) the necrotic
bone of the femoral head under
radiographic guidance







9.3 ± 8.4 Both legs were properly
positioned. Under C-arm and
MRI guidance, the junctional
zone between normal bone and
necrotic bone within the fem-
oral head was delineated. Within
the junctional zone, four points
approximately 1 cm apart were
chosen under C-arm imaging
control and the corresponding
locations were marked on the






































Four points with 1 cm apart
within the junctional zone were
chosen with a metallic pin
under C-arm control, and the
corresponding locations were
marked on the skin in the groin




1 NA None, yes
Al-Abbad et al. BMC Musculoskeletal Disorders          (2020) 21:275 Page 19 of 26
avoiding surrounding areas. Although one study [55] using
radial SWT showed greater reduction in PFT over focused
or combined SWT, these results should be interpreted with
caution based on the small number of studies included in
the subgroup analysis. Despite the observed overall reduc-
tion in PFT in our review that can be correlated with the
improvement in chronic plantar pain [9], it remains unclear
whether the type of SWT generation device is an important
factor for providing the best outcomes [2].
Our meta-analysis data revealed non-significant reduc-
tion in the lesion size with high-over medium and low-
dosage SWT for ONFH. The SWT dose parameters
were fairly consistent among all the included studies.
This could be attributed to the same research group
implementing similar treatment protocols. There are no
previously published reviews or meta-analyses reporting
on imaging changes following SWT among patients with
ONFH to allow results comparisons. However, the ob-
served modest reduction in the size of the lesion could
be correlated with a recently published meta-analysis [8]
that reported significant differences between SWT and
control groups in pain rating and motor function
measures.
Overall, the reported studies support changes in
morphological features based on imaging findings
that may reflect changes in underlying
Table 5 Characteristics of studies and intervention details for osteonecrosis of the femoral head (ONFH) (Continued)
Author
(year)























was adjusted until the two ring
markers of the device synchro-
nized under C-arm imaging
Wang
(2005) [68]
RCT 23(29 hips) 39.8 ±
12.1
5.9 ± 4.5 SWT was applied in the supine
position. The hip was positioned
in adduction and internal
rotation. In patients with a
stage-II or III lesion, the junc-
tional zone between avascular
and vascular bone of the fem-
oral head was delineated under
c-arm control. Four focal points
1 cm apart, within the junctional
zone were selected, and the cor-
responding locations on the skin
in the groin area were marked.
In patients with a stage-I lesion,
the junctional zone was selected











7.5 ± 3 The junctional zone between
the avascular and normal bones
of the femoral head was
delineated with C-arm imaging.
Four points with 1 cm apart
within the junctional zone were
chosen with a metallic pin
under C-arm control, and the
corresponding locations were













7.4 ± 3 The hip joint was properly
positioned by adduction and
internal or external rotation.
Four points with 1 cm apart
within the junctional zone were
chosen with a metallic pin
under C-arm control, and the
corresponding locations were
marked on the skin in the groin
area. The depth of treatment
was adjusted until the two ring
markers of the device synchro-




1 NA None, yes
NR not reported, NA not applicable
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Comparator Imaging outcome Follow-up









None Anteroposterior and lateral
radiographs were obtained to assess
the size of the lesion, the extent of
subchondral bone collapse, and the
presence of degenerative changes in
the hip joint. MRI was performed to
evaluate BME, the size of the lesion,
femoral head congruency, the
presence of a crescent sign, and
degenerative changes in the hip joint
6,12,24
months
The mean size of the lesion (%) over
the femoral head pre-SWT was 59 ±
32 and post-SWT was 28 ± 16.
Significant reduction in BME was
noted following SWT







MRI were assessed for the
congruency of the femoral head,
crescent sign, the size and stage of




The mean size of the lesion (%) over
the femoral head pre-SWT was
23.1 ± 22.2 and post-SWT was 22 ±
23.3.










None MRI examination was performed and




Pre-treatment, the mean edema area
(mm2) was 981.9 ± 453.2. After 2
months was 469.5 ± 306.8. At 6
months, the mean edema area had











Radiographs were used to assess the
size and location of the lesion,
congruency of the femoral head, the
presence of a crescent sign and
degenerative changes of the hip joint.
MRI was used to evaluate the
changes in the size of the lesion, the
congruency of the articular surface of
the femoral head and BME
6,12
months
The mean size of the lesion (%) over
the total femoral head surface was
28.9 ± 14.9 and 27.4 ± 18 before
treatment, and 27.6 ± 14.5 and
26.2 ± 18.5 after treatment for the











None Radiography and MRI were used to
classify the lesions on the ARCO scale
1 year complete healing in 4 patients, a
significant decrease in the size of
the area of poor circulation in 6







None Antero-posterior and lateral
radiographs were used to evaluate
the size of the lesion, the extent of
collapse of subchondral bone and
degenerative changes of the hip joint.
MRI was used to measure the size of
the lesion, assess the congruency of
the femoral head, the presence of a
crescent sign and/or degenerative
changes, with the aim to stage the




At all follow-up time points, the le-
sions show no or only minimal
changes. Neither regression nor pro-
gression of lesions that had been
graded before treatment as ARCO









The necrotic areas of femoral heads
on MRI were estimated on a high
resolution monitor via the PACS
system. The percentage of the
infarcted femoral head volume (IFHV)
was measured by the infarcted
femoral head volume divided by total
femoral head volume. BME around
the necrotic regions were graded on
MRI as follows: grade 0: no BME;
grade 1: peri-necrotic; grade 2: edema
extending to femoral head; grade 3:
edema extending to femoral neck




The mean size of the lesion (%) in
group A pre-SWT was 35.1 ± 9.4 and
post-SWT was 34.2 ± 5.9, group B
pre-SWT was 36.2 ± 8.6 and post-
SWT was 36.6 ± 7.7 and group C pre-
SWT was 30.5 ± 13.1 and post-SWT
was 30.2 ± 7.3.
The IFHV of lesion (%) in group A at
pre-SWT was 20.8 ± 18.7 and post-
SWT was 19.3 ± 19, group B at pre-
SWT was 23 ± 14.1 and post-SWT
was 22.5 ± 16.4, and group C at pre-
SWT was 22.3 ± 15.7 and post-SWT
was 18.9 ± 12.5.
The stage of the lesion showed no
significant differences in all groups.
However, BME on MRI was
significantly reduced after SWT in
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pathophysiological processes. It would appear that
SWT has a clear influence on the morphology of
the reported conditions, although for some condi-
tions there is evidence to suggest that other treat-
ments may have a greater influence on the
underlying pathophysiology and associated morpho-
logical changes.
Limitations of the study
Our aim was to include studies on all kinds of relevant
musculoskeletal conditions that had been treated with any
type of SWT and reporting any imaging outcomes. We
conducted a comprehensive search strategy by including
all possible synonyms to avoid missing any potential rele-
vant trials, hence reducing publication bias. To date, we
are not aware of any previous systematic reviews that eval-
uated changes in musculoskeletal conditions based on im-
aging outcomes following SWT interventions. Publication
bias was not evaluated as there were < 10 trials for each in-
cluded condition; hence, the power of the test would be
very low to distinguish real asymmetry from chance.
The risk of bias scores were 60% for the RCT studies
and 74% for non-RCT studies indicating relatively high
risk of bias. Participant blinding, allocation concealment,





Comparator Imaging outcome Follow-up











MRI was used to examine the size of
the lesion, congruency of the femoral
head, the presence of a crescent sign,
BME and degenerative changes of the
hip joint. The percentage of IFHV was




The mean size of the lesion (%) over
the femoral head pre-SWT was 21 ±
41 and post-SWT was 30 ± 20, 30 ±
20, 26 ± 18 at 1,2, 8–9 years respect-
ively. In the pre-surgical group was
40 ± 23, and post-surgical was 42 ±
15, 41 ± 27, 41 ± 4 at 1,2, 8–9 years
respectively.









None Radiographs were used to assess the
size of the lesion, congruency of the
femoral head, the presence of a
crescent sign and degenerative
changes. MRI was used to evaluate
the changes in lesion size, the





The mean size of the lesion (%) over
the femoral head pre-SWT in the SLE
group was 34.8 ± 21.1 and 28.7 ±
14.2 post-SWT, in the Non-SLE
group, pre-SWT was 32.9 ± 22.4 and
post-SWT was 26.7 ± 12.9. both
groups showed significant reduction
of BME following SWT
> 0.05 > 0.05 for the
size of lesion











Radiographs of the hip joint were
used to evaluate the size of the
lesion, the extent of collapse of
subchondral bone, and degenerative
changes of the hip joint. MRI was
used to examine the size of the
lesion, the congruency of the femoral
head, the presence of a crescent sign,





The mean size of the lesion (%) over
the femoral head pre-SWT was 61 ±
41 and post-SWT was 30 ± 20 at 24
months follow-up. In contrast, the
pre-surgical was 40 ± 23 and post-
surgical was 41 ± 27.
In the SWT group, 5 lesions (3 stage
I and 2 stage II) regressed and 4 (2
stage II and 2 stage III) progressed.
In the surgical group, 4 lesions
regressed, 15 (14 stage II and 1









Radiographs of the hip joint were
used to assess the size of the lesion,
congruency of the femoral head, the
presence of a crescent sign and
degenerative changes of the hip joint.
MRI was used to examine the size of
the lesion, the congruency of the
femoral head, the presence of a
crescent sign, BME, and degenerative




The mean size of the lesion (%) over
the femoral head pre-SWT was
27.7 ± 15.5 and post-SWT was 25.7 ±
16.2 at 6 months follow-up. In con-
trast, the pre-SWT+ alendronate
group was 32.6 ± 19.9 and post-
SWT+ alendronate was 29.32 ± 21.99.
Significant reduction in BME was






None Radiographs in AP and lateral views
were used to assess the size of the
lesion, congruency of the femoral
head, the presence of a crescent sign
and degenerative changes. MRI was
used to evaluate the size of the




The mean size of the lesion (%) over
the femoral head pre-SWT was
27.23 ± 18.9 and 27.04 ± 19.17 post-
SWT. Significant improvement in
BME was noted following SWT
> 0.05 for the
size of lesion




BME bone marrow edema, F-SWT focused SWT, R-SWT radial SWT, NR not reported, NS not significant, NA not applicable
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study size calculation and other sources of bias (defined
according to imaging assessment accuracy) were the
lowest scored items. Of particular interest to this review,
the accuracy of imaging measurements was questionable
in some cases due to the under-reporting of details per-
taining to measurement standardization. It was decided
that meeting a minimum of two out of an a priori set of
four criteria related to imaging accuracy would be used
for judging risk of bias based on imaging accuracy.
These criteria were based on providing details on the ex-
perience or specialty of the radiologist in musculoskel-
etal imaging, details of the imaging procedure to insure
participant’s consistent position during all image acquisi-
tion, prior testing or training of the assessor to ensure
reliability and reporting the score of measurements
based on the average of multiple measurements.
Future research recommendations
Current available research has provided preliminary evidence
related to the capacity of SWT to influence underlying
pathophysiological processes in various musculoskeletal con-
ditions as demonstrated through changes in imaging. How-
ever, considering more standardized and reliable quantitative
imaging measures as a primary outcome would be warranted
in future research. This can be achieved through improving
the imaging outcomes assessment methodology to ensure
consistent and valid reporting based on our suggested cri-
teria for imaging assessment accuracy. Adopting such criteria
can limit the imaging assessment procedure variations as it is
challenging to account for it as a covariate in the interven-
tion effect estimate. Imaging endpoints are recommended to
be specified and reported to evaluate short, medium and
long term changes. Study sample sizes should be calculated
based upon imaging parameters as a primary outcome. It
would also be of great value if researchers could reach con-
sensus on the optimal imaging modality and relevant im-
aging measures for each musculoskeletal disorder.
Consistency of approach would significantly improve the
quality of research.
It was surprising that our comprehensive search
strategy did not identify any studies using imaging
outcomes for commonly treated tendinopathies such
as patellar, proximal hamstring and rotator cuff non-
calcific tendinopathies and identified only a few trials
for Achilles and wrist extensor tendinopathies. This
is an indication of the limited use of imaging as a
measure of outcome in addition to the usual clinical
outcome measures for this type of condition. Whilst
clinical outcomes are clearly of primary importance,
imaging does provide a window to assist us in un-
derstanding the effects and potential mechanism of
action of SWT. Future trials might consider making
Fig. 9 Forest plot of effect of SWT on femoral head necrosis lesion size (%)
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increased use of imaging outcomes in studies of this
nature. This would assist in developing an improved
understanding of the extent to which SWT has a
therapeutic influence on pathophysiological processes
in chronic musculoskeletal disorders.
Conclusions
The current review has identified some changes in im-
aging parameters of musculoskeletal conditions in re-
sponse to SWT. Apparently, dosage parameters of SWT
had no clear influence on the imaging outcomes. Also,
the utilization of radiological guidance and local
anesthesia is questionable. However, the size of lesion is
found to be a potential predictor for change in response
to SWT. Limitations related to imaging modality selec-
tion, timing of imaging and adequate reporting of im-
aging procedures were factors that influenced the
conclusions that could be drawn from the review.
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